Literature DB >> 1656049

X-ray structure of human relaxin at 1.5 A. Comparison to insulin and implications for receptor binding determinants.

C Eigenbrot1, M Randal, C Quan, J Burnier, L O'Connell, E Rinderknecht, A A Kossiakoff.   

Abstract

The X-ray crystal structure of relaxin at 1.5 A resolution is reported for the physiologically active form of the human hormone. Relaxin is a small, two-chain polypeptide that is a member of the protein hormone family that also includes insulin and the insulin-like growth factors IGF-I and IGF-II. These hormones have biologically diverse activities but are structurally similar, sharing a distinctive pattern of cysteine and glycine residues. The predicted structural homology of relaxin to insulin is confirmed by this structural analysis; however, there are significant differences in the terminal regions of the b-chain. Although relaxin, like insulin, crystallizes as a dimer, the orientation of the molecules in the respective dimers is completely different. The region of the relaxin molecule proposed to be involved in receptor binding is part of the dimer interface, suggesting that some of the other residues contained in the dimer contact surface might be receptor binding determinants as well. The proposed receptor binding determinants for insulin likewise include residues at its dimer interface. However, because the dimer contacts of relaxin and insulin are quite different, it appears that these two structurally related hormones have evolved somewhat dissimilar mechanisms for receptor binding.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656049

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  19 in total

Review 1.  New Insights into biological roles of relaxin and relaxin-related peptides.

Authors:  Jae-Il Park; Chia Lin Chang; Sheau Yu Teddy Hsu
Journal:  Rev Endocr Metab Disord       Date:  2005-12       Impact factor: 6.514

2.  Chemical pathways of peptide degradation. X: effect of metal-catalyzed oxidation on the solution structure of a histidine-containing peptide fragment of human relaxin.

Authors:  M Khossravi; R T Borchardt
Journal:  Pharm Res       Date:  2000-07       Impact factor: 4.200

Review 3.  Relaxin family peptides: structure-activity relationship studies.

Authors:  Nitin A Patil; K Johan Rosengren; Frances Separovic; John D Wade; Ross A D Bathgate; Mohammed Akhter Hossain
Journal:  Br J Pharmacol       Date:  2017-01-19       Impact factor: 8.739

Review 4.  Insulin: a small protein with a long journey.

Authors:  Qingxin Hua
Journal:  Protein Cell       Date:  2010-06       Impact factor: 14.870

Review 5.  Principles of protein-protein interactions.

Authors:  S Jones; J M Thornton
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

Review 6.  Assessment and significance of protein-protein interactions during development of protein biopharmaceuticals.

Authors:  Sandeep Yadav; Jun Liu; Thomas M Scherer; Yatin Gokarn; Barthélemy Demeule; Sonoko Kanai; James D Andya; Steven J Shire
Journal:  Biophys Rev       Date:  2013-03-14

7.  The kinetics of relaxin oxidation by hydrogen peroxide.

Authors:  T H Nguyen; J Burnier; W Meng
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

Review 8.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

9.  Solution structure of a conformationally restricted fully active derivative of the human relaxin-like factor.

Authors:  Erika E Büllesbach; Mathias A S Hass; Malene R Jensen; D Flemming Hansen; Søren M Kristensen; Christian Schwabe; Jens J Led
Journal:  Biochemistry       Date:  2008-12-16       Impact factor: 3.162

10.  Structure of the R3/I5 chimeric relaxin peptide, a selective GPCR135 and GPCR142 agonist.

Authors:  Linda M Haugaard-Jönsson; Mohammed Akhter Hossain; Norelle L Daly; Ross A D Bathgate; John D Wade; David J Craik; K Johan Rosengren
Journal:  J Biol Chem       Date:  2008-06-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.